CAC2 Childhood Cancer Community News Digest (April 17-23)
Assorted News from the Last Week:
Children with acute lymphoblastic leukemia (ALL) who live in extreme poverty and were undergoing maintenance therapy faced an almost two-fold greater risk of relapse compared with kids who weren’t as poor.
Scientists at Children’s Hospital Los Angeles (CHLA) have created a liquid biopsy (LB) for pediatric solid tumors that can help diagnose specific types of cancer when traditional biopsies are not feasible.
The combination of olaparib and the investigational ATR inhibitor ceralasertib induced antitumor responses in children and adolescents with DNA repair-deficient tumors in neuroblastoma patients. (free, but requires site registration)
Results from a new study add to the evidence that programs aimed at reducing the financial burden of cancer treatment can save money and improve the quality of life of people with cancer and their loved ones.
A new type of targeted therapy, a drug called revumenib, shows promise for acute myeloid leukemia (AML), one of the most difficult leukemias to treat.
General review of the potential of DFMO as a promising therapy for neuroblastoma.
A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair deficiencies.
A study reporting phase 2 clinical trial results treating the brain tumor craniopharyngioma with proton therapy found a similar survival rate between more targeted proton therapy and photon therapy but improved neurocognitive outcomes with the proton therapy.
The White House plans to nominate NCI Director Monica Bertagnolli, a cancer surgeon to lead the National Institutes of Health.
Upcoming Webinars, Online Opportunities, and Meetings:
Triage Cancer will host a free webinar at 1:00 pm ET on Wednesday May 17. The speakers will discuss COBRA, the medical marketplace, Medicare, Medicaid, and much more. Learn how to compare options to find an affordable plan that meets individual needs. Click here for more information and to register.
Registration has opened for the CAC2 2023 Annual Summit, presented by Day One Biopharmaceuticals! This year’s conference takes place from noon, Monday, June 19 through 2:00 pm, Wednesday, June 21, 2023, in Atlanta, GA, at Children’s Healthcare of Atlanta Emory University. Click here for more information and to register.
MIB Agents Osteosarcoma Alliance FACTOR 2023 Conference brings together the leading osteosarcoma researchers and clinicians, along with patient families and OsteoWarriors (survivors, patients and siblings of OsteoWarriors and OsteoAngels) to Make It Better for those battling this disease. Click here for more information.
Childhood Cancer Action Day (sponsored by our friends at the Alliance of Childhood Cancer) has three asks for your federal legislators this year. Click to learn more.
The Communication Team at the Childhood Cancer Data Initiative is hoping to identify personal stories from the patient/caregiver/survivor perspective to feature in their monthly newsletter debuting next month. Each month the CCDI progress update will include three stories of people in the childhood cancer community that either relate directly to childhood cancer data sharing or allow them to highlight a need that CCDI would help meet. Please email Vickie at of you have a story or would like more information.
Sign up to receive a copy of CAC2's free childhood cancer news digest in your inbox each week.
- Blog Posts (65)
- Guest Blogs (18)
- Member Blogs (24)
- Survivorship Matters Blog (9)
- CAC2 News (22)
- Collaborative Achievements (13)
- Community News (170)
- News Digest (130)
- Research Explained (10)
- Webinars (62)